Victoza® (liraglutide) is the second drug in a new class of injectable diabetes medications, called GLP-1 analogs. It will be available in Europe in 2009, but is not yet approved in the United States.
liraglutide
- Brand name: Victoza®
- Class: Glucagon-Like Peptide-1 (GLP-1) analogue
- For: Type 2 diabetes
- Route of Administration: once-daily injection
- Action:
mimicks GLP-1,
allowing secretion of insulin by beta cells.
Also delays gastric emptying, and suppresses meal-related glucagon secretion.
- Manufacturer: Novo Nordisk
- Status: Approved in Europe July 3 2009.
Undergoing FDA review as of July 2009.
- Source: Press release from manufacturer,
Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe (3 July 2009)
- Availability:
To be available in the UK, Germany and Denmark in the summer of 2009, and in other European markets during the second half of 2009 and throughout 2010.
- Other drugs in the same class:
Byetta (exenatide) (approved in US and Europe).
Also see
liraglutide
At Wikipedia.
Novo Nordisk says Victoza cleared for EU market At Reuters.
|
|
|
